Praxis Precision Medicines, Inc. SEC Filings

Praxis Precision Medicines, Inc. reported an insider equity transaction by its Principal Accounting Officer, Lauren Mastrocola. On January 7, 2026, 35 shares of Praxis common stock were withheld by the company at a price of $292.63 per share to cover tax obligations tied to the vesting of previously reported restricted stock units. After this tax withholding, Mastrocola beneficially owns 10,406.656 shares of Praxis common stock directly.

Praxis Precision Medicines General Counsel and Secretary Alex Nemiroff reported an automatic share withholding related to equity compensation. On January 7, 2026, 89 shares of common stock were withheld by the company at a price of $292.63 per share to cover tax obligations tied to the vesting of previously reported restricted stock units. After this tax withholding event, Nemiroff beneficially owned 20,742.667 shares of Praxis Precision Medicines common stock, held directly.

Praxis Precision Medicines, Inc. reported an insider equity transaction by its Chief Financial Officer, Kelly Timothy Edwin. On 01/07/2026, 139 shares of common stock were withheld by the company at a price of $292.63 per share to satisfy tax withholding obligations related to the vesting of previously reported restricted stock units. Following this tax-related withholding, the officer directly beneficially owned 24,524 shares of Praxis common stock.

Praxis Precision Medicines Chief Executive Officer Marcio Souza reported an automatic share disposition related to tax withholding. On January 7, 2026, 405 shares of common stock were withheld by the company at a price of $292.63 per share to satisfy tax obligations tied to the vesting of previously reported restricted stock units. This was not an open-market sale. After this transaction, Souza beneficially owned 53,502 common shares directly and an additional 2,600 common shares indirectly, which are held by his spouse.

Praxis Precision Medicines, Inc. (PRAX) filed an initial ownership report for Chief Operating Officer Megan Sniecinski as of January 1, 2026. She beneficially owns 20,877 shares of common stock, which include unvested restricted stock units that settle in common shares. In addition, she holds multiple stock options covering blocks of common stock at exercise prices ranging from $31.8 to $257.25, with vesting schedules spanning several years and expirations extending to 2035. All reported holdings are listed as directly owned.

Praxis Precision Medicines reported leadership changes. The company appointed Megan Sniecinski as Chief Operating Officer, effective January 1, 2026. She previously served as Chief Business Officer since 2021 and has held senior roles at BioCryst Pharmaceuticals, PTC Therapeutics and Merck. In connection with her new role, her annual base salary was set at $626,000 with a 2026 target bonus equal to 50% of base salary, and she will continue to participate in standard executive employment and indemnification arrangements.

The Board also elected Jeffrey B. Kindler and Stuart A. Arbuckle as independent Class II directors, each serving until the 2028 annual meeting of stockholders or until a successor is elected and qualified. Both will receive compensation under the company’s Non-Employee Director Compensation Policy, including an initial stock option award, annual cash retainer and annual stock option award. Each entered into the company’s standard indemnification agreement, and there are no related person transactions or special arrangements tied to their selection.

Praxis Precision Medicines, Inc. entered into an underwriting agreement for an underwritten public offering of 2,212,000 shares of its common stock at $260.00 per share. Underwriters were also granted an option to purchase up to 331,800 additional shares, which was exercised in full on January 7, 2026. Net proceeds from the offering are expected to be approximately $621.2 million after underwriting discounts, commissions and estimated expenses.

The company plans to use the cash, together with existing cash, cash equivalents and marketable securities, to prepare for potential commercialization of late-stage product candidates, continue research and development of clinical-stage and earlier-stage programs, and for working capital and general corporate purposes. Praxis believes this funding, combined with current resources, will be sufficient to cover operating expenses and capital expenditure requirements into 2028, although this depends on assumptions that may change.

Praxis Precision Medicines, Inc. is issuing 2,212,000 shares of common stock at $260.00 per share in an underwritten public offering, with underwriters holding a 30-day option to buy up to 331,800 additional shares. The deal is expected to generate approximately $540.1 million in net proceeds, which, combined with about $925 million in cash, cash equivalents and marketable securities as of December 31, 2025, is expected to fund operating needs into 2028.

The company plans to use the cash to prepare for potential commercialization of late-stage product candidates, continue clinical development, advance earlier-stage CNS programs, and for general corporate purposes. Shares outstanding will increase from 25,195,092 to 27,407,092 after the offering (excluding the option), and new investors face dilution of $222.20 per share based on an as adjusted net tangible book value of $37.80 versus the $260.00 offering price.

Praxis Precision Medicines reported preliminary year-end liquidity, stating that as of December 31, 2025 its cash, cash equivalents and marketable securities totaled approximately $925 million. This figure is based on unaudited internal information and management estimates for the year and is still subject to the company’s normal year-end closing procedures.

The company emphasized that its independent registered public accounting firm has not audited or reviewed this estimate and does not provide any assurance on it. The disclosure is being furnished rather than filed, meaning it is provided for investor information but is not automatically incorporated into other securities law filings unless specifically referenced.